HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transmissible spongiform encephalopathies

This article was originally published in The Rose Sheet

Executive Summary

FDA advisory committee scheduled to meet April 15-16 to discuss and make recommendations on the safety of tallow and tallow derivatives used in cosmetics, pharmaceuticals and other FDA regulated products. U.S. and global issues on edible and non-edible tallow will also be considered. The European Union recently approved a BSE tallow exemption excluding the ingredient from a ban on the use of specified risk materials derived from sources potentially afflicted with TSE ("The Rose Sheet" March 16, In Brief). On April 16, the committee will discuss gelatin and dura mater products. The meeting will be held at the Holiday Inn, Bethesda, Md...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS005275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel